Breast cancer susceptibility is associated with germline mutations in several genes such as BRCA1, BRCA2, PTEN, TP53, PALB2, CDH1 and STK11, and genes of moderate penetrance like ATM and CHEK2. 2 Next-generation sequencing (NGS) technology has enabled panel based genetic testing to the clinic, providing cost savings and the ability to test many genes simultaneously.3 However, the disadvantage of panel testing is the increased probability of encountering a germline VUS. This evidence concerns the gene PALB2 and breast carcinoma.